Equities Analysts Offer Predictions for Esperion Therapeutics, Inc.’s FY2025 Earnings (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Research analysts at Zacks Research lowered their FY2025 earnings per share (EPS) estimates for Esperion Therapeutics in a note issued to investors on Tuesday, October 8th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings of $0.09 per share for the year, down from their previous forecast of $0.14. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.04) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q4 2025 earnings at $0.24 EPS.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.10. The business had revenue of $73.83 million during the quarter, compared to analysts’ expectations of $51.90 million.

Other analysts have also recently issued research reports about the company. Bank of America cut Esperion Therapeutics from a “neutral” rating to an “underperform” rating and reduced their price objective for the company from $2.90 to $2.50 in a research report on Thursday, June 20th. StockNews.com raised Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, October 5th. Needham & Company LLC lowered their target price on Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, August 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Wednesday, October 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, Esperion Therapeutics has a consensus rating of “Hold” and a consensus price target of $8.17.

Esperion Therapeutics Price Performance

ESPR stock opened at $1.89 on Thursday. Esperion Therapeutics has a 1-year low of $0.70 and a 1-year high of $3.40. The business has a fifty day moving average price of $1.82 and a 200-day moving average price of $2.19. The stock has a market capitalization of $358.08 million, a P/E ratio of -1.91 and a beta of 1.00.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. BOKF NA purchased a new stake in Esperion Therapeutics in the second quarter worth about $26,000. Xponance Inc. purchased a new stake in Esperion Therapeutics in the second quarter worth about $28,000. CVI Holdings LLC purchased a new stake in Esperion Therapeutics in the first quarter worth about $37,000. Sivia Capital Partners LLC purchased a new stake in Esperion Therapeutics in the second quarter worth about $44,000. Finally, National Bank of Canada FI increased its position in Esperion Therapeutics by 115.9% in the second quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 10,225 shares in the last quarter. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.